Literature DB >> 11274323

Outcomes following staged bilateral pallidotomy in advanced Parkinson's disease.

T J Counihan1, L A Shinobu, E N Eskandar, G R Cosgrove, J B Penney.   

Abstract

The authors assessed clinical outcome for up to one year after staged bilateral pallidotomy in 14 patients with advanced PD. One year after surgery, dyskinesias were virtually abolished and there were significant reductions in "off" time (67%) and activities of daily living "off" scores (24%), as well as nonsignificant reduction in "off" motor score (39%); "on" scores were unchanged. One patient developed a visual field deficit; two had transient confusion. Staged bilateral pallidotomy improves motor function in selected patients with advanced PD.

Entities:  

Mesh:

Year:  2001        PMID: 11274323     DOI: 10.1212/wnl.56.6.799

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Focused Ultrasound: An Emerging Therapeutic Modality for Neurologic Disease.

Authors:  Paul S Fishman; Victor Frenkel
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 2.  What happened to posteroventral pallidotomy for Parkinson's disease and dystonia?

Authors:  Robert E Gross
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

3.  Bilateral MR-Guided Focused Ultrasound Pallidothalamic Tractotomy for Parkinson's Disease With 1-Year Follow-Up.

Authors:  Marc N Gallay; David Moser; Anouk E Magara; Fabio Haufler; Daniel Jeanmonod
Journal:  Front Neurol       Date:  2021-02-09       Impact factor: 4.003

Review 4.  Surgical treatment of dyskinesia in Parkinson's disease.

Authors:  Renato P Munhoz; Antonio Cerasa; Michael S Okun
Journal:  Front Neurol       Date:  2014-04-29       Impact factor: 4.003

5.  Safety and efficacy of unilateral and bilateral pallidotomy for primary dystonia.

Authors:  Shiro Horisawa; Atsushi Fukui; Nobuhiko Takeda; Takakazu Kawamata; Takaomi Taira
Journal:  Ann Clin Transl Neurol       Date:  2021-03-15       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.